GlassScriptPhysician profile
Jennifer Ball
NPI 1386635548
$2,405.85
in general payments reported to CMS, 2019-2025
28 companies · $928 in 2025
The $928 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $19.65 · 2021: $39.00 · 2022: $370 · 2023: $427 · 2024: $473 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811 · Education: $16.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.09 |
| Education | $16.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $448.37 | 2021-2025 | Trodelvy |
| Ge Healthcare | $224.65 | 2025 | |
| Celgene Corporation | $207.77 | 2022-2024 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $192.86 | 2022-2025 | |
| Abbvie INC. | $177.41 | 2022-2025 | |
| Pfizer INC. | $163.89 | 2022-2025 | |
| Array Biopharma INC | $139.99 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Janssen Biotech, INC. | $91.97 | 2022-2025 | Akeega, Balversa, Erleada |
| Pharmacyclics LLC, An Abbvie Company | $90.76 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $83.98 | 2019-2025 | Keytruda, Capvaxive, Vaxneuvance |
| Pharmaessentia USA Corporation | $67.70 | 2023-2024 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $60.45 | 2022-2024 | Opdivo |
| Glaxosmithkline, LLC. | $46.26 | 2025 | Ojjaara, Blenrep |
| Genzyme Corporation | $41.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.77 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $40.64 | 2019 | |
| Astellas Pharma US INC | $37.89 | 2024-2025 | Xtandi, Xospata |
| Seagen INC. | $33.96 | 2022-2023 | Adcetris |
| Dendreon Pharmaceuticals LLC | $32.35 | 2025 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $28.57 | 2024 | Fruzaqla |
| Amgen INC. | $27.78 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $21.51 | 2023 | |
| Sumitomo Pharma America, INC. | $21.13 | 2025 | Orgovyx |
| Genentech USA, INC. | $20.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.39 | 2019 | |
| Rigel Pharmaceuticals, INC. | $16.95 | 2023-2024 | Tavalisse, Rezlidhia |
| Exelixis INC. | $14.87 | 2024 | Cabometyx |
| Myovant Sciences INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.